Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Odalasvir PK and QT/QTc Study in Healthy Subjects
NCT02889367Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2016
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of odalasvir in hepatitis C (HCV) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Relationship Between Plasma Concentrations of Odalasvir and Changes in QT/QTc Interval. Started Sep 2016; status: completed.
02
Drugs
odalasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02889367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02889367.